ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Mallinckrodt Receives Approval in Japan of the CELLEX® Extracorporeal Photopheresis System for Treatment of Chronic Graft Versus Host Disease
February 01, 2021DUBLIN – January 27, 2021 – Mallinckrodt plc, a global biopharmaceutical company, announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) approved the CELLEX® extracorporeal photopheresis (ECP) system. -
FDA Approves Imbruvica (ibrutinib) for Chronic Graft Versus Host Disease
August 03, 2017The U.S. Food and Drug Administration today expanded the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more treatments. This is the first FDA-approved therapy f
Pharma Sources Insight January 2025
